Petaluma medtech startup Oculus licenses technology for acne drug

STEVE HART
THE PRESS DEMOCRAT

Petaluma medical technology startup Oculus Innovative Sciences has licensed its product for a potential acne drug.

New Jersey-based AmDerma Pharmaceuticals exercised its option to license rights to Oculus' Microcyn technology for development of the skin medication, Oculus officials said last week.

Microcyn is an anti-infection liquid used in dermatology, wound care, oral care, cosmeceuticals and veterinary care.

Oculus sells Microcyn products in the U.S., Mexico, Europe, India, China and parts of the Middle East.

AmDerma also licensed the rights to help Oculus promote existing Microcyn-based wound care products in the U.S. podiatry market, and licensed U.S. and Canadian rights to a Microcyn-based dermatology atopic dermatitis hydrogel that received FDA clearance in February.

UPDATED: Please read and follow our commenting policy:
  • This is a family newspaper, please use a kind and respectful tone.
  • No profanity, hate speech or personal attacks. No off-topic remarks.
  • No disinformation about current events.
  • We will remove any comments — or commenters — that do not follow this commenting policy.
Send a letter to the editor